Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Promethera

- PMLiVE

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

- PMLiVE

Roche to acquire 89bio in a deal worth up to US$3.5bn

With the agreement, Roche will gain a treatment for moderate to severe MASH

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

- PMLiVE

Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

The drug has already been approved in the US to treat patients with non-cirrhotic MASH

- PMLiVE

Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

- PMLiVE

Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

Primary biliary cholangitis affects approximately 163,000 people in Europe

- PMLiVE

Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

The company gained access to the drug through its $4.3bn acquisition of CymaBay

- PMLiVE

GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial

An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030

- PMLiVE

Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis

The rare liver disease affects approximately 100,000 people in the US

- PMLiVE

Medscape Publication is Awarded Poster of Distinction at AASLD

Medscape Education is committed to disseminating the outcomes of the education programs through peer-reviewed publications and posters at leading medical conferences around the world. To this end, Medscape publishes more...

Medscape Education

- PMLiVE

Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

The disease affects approximately 25,000 people in the UK, the majority of whom are women

- PMLiVE

Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

Approximately 25,000 people in the UK are affected by the rare liver disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links